Guangzhou Wondfo BiotechLtd

SZSE:300482 Stock Report

Mkt Cap: CN¥19.4b

We’ve recently updated our valuation analysis.

Guangzhou Wondfo BiotechLtd Valuation

Is 300482 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300482?

Other financial metrics that can be useful for relative valuation.

300482 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA12.8x
PEG Ratio-2.4x

Price to Earnings Ratio vs Peers

How does 300482's PE Ratio compare to its peers?

The above table shows the PE ratio for 300482 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average43.6x
300171 Tofflon Science and Technology Group
18.7x23.6%CN¥16.4b
688617 APT Medical
62x32.6%CN¥19.0b
688139 Qingdao Haier Biomedical
36.1x27.8%CN¥22.0b
301367 BMC Medical
57.6xn/aCN¥17.1b
300482 Guangzhou Wondfo BiotechLtd
15.6x-6.5%CN¥19.4b

Price-To-Earnings vs Peers: 300482 is good value based on its Price-To-Earnings Ratio (15.6x) compared to the peer average (43.6x).


Price to Earnings Ratio vs Industry

How does 300482's PE Ratio compare vs other companies in the CN Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.3%
n/an/an/a

Price-To-Earnings vs Industry: 300482 is good value based on its Price-To-Earnings Ratio (15.6x) compared to the CN Medical Equipment industry average (33.7x)


Price to Earnings Ratio vs Fair Ratio

What is 300482's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300482 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.6x
Fair PE Ratio17.4x

Price-To-Earnings vs Fair Ratio: 300482 is good value based on its Price-To-Earnings Ratio (15.6x) compared to the estimated Fair Price-To-Earnings Ratio (17.4x).


Share Price vs Fair Value

What is the Fair Price of 300482 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300482 (CN¥43.93) is trading below our estimate of fair value (CN¥51.1)

Significantly Below Fair Value: 300482 is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300482 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥43.93
CN¥58.76
+33.8%
25.0%CN¥73.44CN¥44.08n/a2
Nov ’23CN¥31.78
CN¥60.42
+90.1%
20.2%CN¥73.44CN¥44.08n/a3
Oct ’23CN¥29.33
CN¥68.59
+133.8%
7.1%CN¥73.44CN¥63.73n/a2
Sep ’23CN¥33.06
CN¥68.59
+107.5%
7.1%CN¥73.44CN¥63.73n/a2
Aug ’23CN¥36.37
CN¥68.59
+88.6%
7.1%CN¥73.44CN¥63.73n/a2
Jul ’23CN¥40.66
CN¥68.59
+68.7%
7.1%CN¥73.44CN¥63.73n/a2
Jun ’23CN¥39.00
CN¥68.59
+75.9%
7.1%CN¥73.44CN¥63.73n/a2
May ’23CN¥43.63
CN¥63.73
+46.1%
0%CN¥63.73CN¥63.73n/a1
Apr ’23CN¥48.14
CN¥68.73
+42.8%
7.5%CN¥73.87CN¥63.59n/a2
Mar ’23CN¥43.93
CN¥55.86
+27.2%
13.8%CN¥63.59CN¥48.13n/a2
Feb ’23CN¥36.60
CN¥55.86
+52.6%
13.8%CN¥63.59CN¥48.13n/a2
Jan ’23CN¥39.38
CN¥55.86
+41.8%
13.8%CN¥63.59CN¥48.13n/a2
Dec ’22CN¥37.30
CN¥55.86
+49.8%
13.8%CN¥63.59CN¥48.13n/a2
Nov ’22CN¥35.38
CN¥55.86
+57.9%
13.8%CN¥63.59CN¥48.13CN¥31.782
Oct ’22CN¥43.00
CN¥68.96
+60.4%
7.8%CN¥74.32CN¥63.59CN¥29.332
Sep ’22CN¥42.39
CN¥73.45
+73.3%
1.2%CN¥74.32CN¥72.58CN¥33.062
Aug ’22CN¥53.99
CN¥87.34
+61.8%
16.9%CN¥102.10CN¥72.58CN¥36.372
Jul ’22CN¥63.74
CN¥87.34
+37.0%
16.9%CN¥102.10CN¥72.58CN¥40.662
Jun ’22CN¥72.20
CN¥87.34
+21.0%
16.9%CN¥102.10CN¥72.58CN¥39.002
May ’22CN¥78.02
CN¥87.34
+11.9%
16.9%CN¥102.10CN¥72.58CN¥43.632
Apr ’22CN¥63.08
CN¥83.54
+32.4%
0%CN¥83.54CN¥83.54CN¥48.141
Mar ’22CN¥57.37
CN¥83.15
+44.9%
0%CN¥83.15CN¥83.15CN¥43.931
Feb ’22CN¥67.60
CN¥79.42
+17.5%
4.7%CN¥83.15CN¥75.69CN¥36.602
Jan ’22CN¥68.62
CN¥79.42
+15.7%
4.7%CN¥83.15CN¥75.69CN¥39.382
Dec ’21CN¥50.77
CN¥75.69
+49.1%
0%CN¥75.69CN¥75.69CN¥37.301
Nov ’21CN¥58.62
CN¥75.69
+29.1%
0%CN¥75.69CN¥75.69CN¥35.381

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies